Navigation Links
Otonomy Presents Positive New Findings From Phase 1b Study of OTO-104 in Meniere's Disease at International Conference
Date:9/29/2011

SAN DIEGO, Calif., Sept. 29, 2011 /PRNewswire/ -- Otonomy, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the inner and middle ear, today announced that researchers presented positive new data from a Phase 1b study of the company's lead product candidate, OTO-104, in patients with Meniere's disease.  The presented data showed that patients treated with OTO-104 experienced clinically meaningful reductions in vertigo frequency and improvements in tinnitus as compared to placebo.  These results were presented today in an oral presentation at the 28th Politzer Society Meeting in Athens, Greece.

Researchers presented findings showing clinically meaningful reductions in vertigo frequency at three months with the 12 mg OTO-104 dose as compared to placebo.  Prior to treatment, patients in both the 12 mg OTO-104 and placebo groups experienced an average of eight days with definitive vertigo episodes during a baseline period of one month. Following a single intratympanic (IT) injection, patients in the 12 mg OTO-104 group experienced a month-over-month reduction in vertigo frequency throughout the three month follow-up period, and achieved an approximate six day reduction in the number of definitive vertigo days in the third month versus baseline. When compared to placebo, at three months following treatment, the 12 mg study group experienced a 70 percent greater reduction from baseline in the number of days with definitive vertigo episodes.  There was no clinically meaningful difference in vertigo frequency between the 3 mg OTO-104 and placebo groups at three months following treatment.

Additionally, the presented study data demonstrated that both the 3 mg and 12 mg OTO-104 doses were associated with improvement in tinnitus as measured by the Tinnitus Handicap Inventory (THI-25). THI is a clinically validated patient-reported measure that can be used to quantify th
'/>"/>

SOURCE Otonomy, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Otonomy Introduces Scientific Advisory Board
2. Otonomys OTO-104 Demonstrates Hearing Loss Protection and Hearing Recovery in Preclinical Studies
3. Otonomy Appoints Gerald Wroblewski as Chief Operations Officer
4. Bluestar Silicones Presents Adhesive Gels for Wound Care at Medical Grade Polymers Conference
5. Acologix Presents Preclinical Data on Cartilage Regeneration by AC-100 at the 30th ASBMR Annual Meeting
6. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
7. MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease
8. GeoVax Presents Data at AIDS Vaccine 2008 Conference
9. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
10. MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology
11. Northern Antibiotics Presents New Data on Novel Polymyxin Compounds at the Joint ICAAC/IDSA 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... 26, 2015  The Diabetes Research Institute (DRI), ... Miami Miller School of Medicine, announced today that ... test for the first time a novel transplant ... FDA approved Phase I/II study builds upon decades ... an important first step toward the development of ...
(Date:8/26/2015)... Intrexon Corporation (NYSE: XON ), a ... its previously announced public offering of common stock, including ... option to purchase an additional 731,707 shares of common ... share.  The exercise of the underwriters, option brought the ... Intrexon to 5,609,756 shares and increased the total gross ...
(Date:8/26/2015)... 2015 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, hematopoietic ... announced that the Company has been informed that Magnum ... owned by Mr. Yuen Kam, chairman of the board ... shares (the "Shares") of  Excellent China Healthcare Investment Limited ...
(Date:8/26/2015)... CORAL SPRINGS, Florida , August 26, 2015 ... one of the biggest factors fueling the optimism ... FDA approvals, M&A,s, collaborations and life sciences advancements.  ... and developments are Pressure BioSciences, Inc. (OTCQB: PBIO), ... Inc. (NASDAQ: SRPT ), Raptor Pharmaceutical Corp. ...
Breaking Biology Technology:Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 2New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 4New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 5New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 6New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 7
... 29, 2011 USChina Channel LLC announced today: ... Inc. ("CBI") filed Form 8-k of SEC, to announce the ... process is going very well. We already have ... the vote. Followings are the interim vote results for the ...
... Morphotek®, Inc., a subsidiary of Eisai Inc., ... collaboration and license agreement with Biocare Medical, LLC. ... develop and commercialize an immunohistochemical (IHC) diagnostic kit ... human folate receptor alpha (FRA) with Biocare,s intelliPATH™ ...
... NEW YORK, March 29, 2011 Reportlinker.com ... is available in its catalogue: ... and Europe - Development and Approval of ... http://www.reportlinker.com/p0464103/Biosimilars-Approval-Pathways-in-the-US-and-Europe---Development-and-Approval-of-Biosimilar-mABs-May-Face-Tough-Regulatory-Environment.html ...
Cached Biology Technology:Commonwealth Biotechnologies 2011 Annual Shareholder Vote & Meeting Update Information 2Commonwealth Biotechnologies 2011 Annual Shareholder Vote & Meeting Update Information 3Morphotek®, Inc. Announces an Agreement with Biocare Medical, LLC to Develop and Commercialize A Diagnostic Kit for Detection of Folate Receptor Alpha in Malignant Tissues 2Morphotek®, Inc. Announces an Agreement with Biocare Medical, LLC to Develop and Commercialize A Diagnostic Kit for Detection of Folate Receptor Alpha in Malignant Tissues 3Reportlinker Adds Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment 2Reportlinker Adds Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment 3Reportlinker Adds Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment 4Reportlinker Adds Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment 5Reportlinker Adds Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment 6Reportlinker Adds Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment 7Reportlinker Adds Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment 8Reportlinker Adds Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment 9Reportlinker Adds Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment 10Reportlinker Adds Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment 11Reportlinker Adds Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment 12Reportlinker Adds Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment 13
(Date:8/12/2015)... August 12, 2015 As the ... payment innovation and advanced biometrics technology is accelerating beyond ... consumers rely on using their credit cards, the digital ... future for payment services led by companies in the ... :  Google, Inc. (NASDAQ: GOOG ), Apple Inc. ...
(Date:8/11/2015)... -- Today, ZUK announced its Android smartphone Z1, featuring ... revenues in 2015 that relate to sales of FPC1155 for this ... 2,200 MSEK for 2015. Jörgen Lantto, CEO of FPC, ... smartphone manufacturer in China and we ... 155 for Z1 , ...
(Date:8/6/2015)... REDWOOD CITY, Calif. , Aug. 6, 2015 ... (D-Silicon Valley) will visit Crossmatch ™ to ... secure networks and protect data. Crossmatch is a ... solutions whose technologies and expertise are helping federal ... operational efficiency and security.   "The ...
Breaking Biology News(10 mins):Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Rep. Honda to Visit Crossmatch in Redwood City 2
... BUFFALO, NY -- Exposure to air pollution early in ... child may alter her DNA and may be associated with ... at Buffalo have shown. The findings indicated that higher ... may increase levels of E-cadherin, a protein important to the ...
... won $100 and then offered you a few dollars, would ... be, sure, why not? "But human decision making does not ... Virginia Tech and director of the Human Neuroimaging Laboratory at ... research conducted over the last three decades; only about one-fourth ...
... of the Deepwater Horizon oil spill that took the lives ... of coastal Louisiana, it,s difficult to put the complicated relationship ... have thus far not been as pervasive as originally feared, ... too early to tell. However, dependence upon oil has not ...
Cached Biology News:Air pollution exposure affects chances of developing premenopausal breast cancer 2Functional MRI shows how mindfulness meditation changes decision-making process 2Functional MRI shows how mindfulness meditation changes decision-making process 3Shades of gray: LSU researcher studies South Louisiana's historical ties to the oil industry 2Shades of gray: LSU researcher studies South Louisiana's historical ties to the oil industry 3Shades of gray: LSU researcher studies South Louisiana's historical ties to the oil industry 4Shades of gray: LSU researcher studies South Louisiana's historical ties to the oil industry 5
... Features, Special optically clear polystyrene formulation ... in immunoassay applications , Plates are ... coefficients of variation , Eight-well strips ... strip loss while in use even if ...
...
... Pierce scientists developed the Easy-Titer Human IgM ... a simple, sensitive, and easy-to-perform assay for ... an ELISA. This kit incorporates a simple ... of IgM concentration from 15-500 ng/ml in ...
... Lipid adsorption and clarification reagent; ... the purification of antibodies, proteins, nucleic ... has negligible cross-reactivity, and improves downstream ... a solid-phase, non-ionic adsorbent supplied as ...
Biology Products: